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Abstract
Title: Effect of CPAP Compliance on a Cognitive Screening Test in a Memory Clinic
Population with Sleep Apnea
Author: Tatiana Marie Vallejo-Luces, M.S.
Major Advisor: Frank Webbe, Ph.D.

Objectives: To determine whether the Montreal Cognitive Assessment (MoCA) was a
sensitive indicator of cognitive improvement following introduction of continuous
positive airway pressure (CPAP) in community memory clinic (CMC) patients who
had been diagnosed with sleep apnea (SA).
Method: Twenty-six CPAP compliant CMC patients (61.5% male; 96.2%
Caucasian/Non-Hispanic) with a diagnosis of SA (66-87 years (M=76.27(4.90))
completed a MoCA before initiation of treatment and again 4-9 months later. CPAP
compliance was documented through CPAP machine compliance reports and/or
clinical interview with patient and family member during subsequent medical visits.
Twenty CPAP non-compliant CMC patients (85% male, 100% Caucasian/NonHispanic; 66-90 years (M=77.45 (6.88)) similarly diagnosed with SA completed
MoCAs before initiation of treatment and again 4-8 months later. CMC diagnoses of
the patients included: no cognitive impairment, Alzheimer’s disease, mild cognitive
impairment, cognitive disorder NOS, or other dementia.
iii

Results: Post-treatment MoCA scores for the CPAP compliant group (M= 22.27) were
significantly higher than pre-treatment scores (M= 20.38; t(25)= -4.992; p<0.001).
Nineteen of the 26 compliant individuals evidenced increases in MoCA, three
remained the same, and four declined. The non-compliant group showed no change
over time (MoCA pre- M= 19.90, MoCA post- M= 20.50; t(19)= -.798; p= .435), with
seven scores decreasing, eleven increasing, and two remaining the same. There was no
significant interaction between CPAP compliance groups and MoCA change scores,
Wilks’ Lambda= .94, F (1, 44) = 2.67, partial eta squared= .057.
Conclusions: More patients with SA who complied with CPAP recommendation
demonstrated improved MoCA performance than did those who did not comply with
the recommendation. Within-subject comparison of pre- and post-CPAP usage via
paired t-test was significant only for the compliant group. Finding no effect on change
score or interaction between MoCA test time and compliance using the mixed-model
ANOVA was likely due to the relative small sample size, which did not supply
sufficient power to the study. This interpretation is supported by the t-test outcome as
well as the numerical difference in numbers of patients whose MoCA scores increased
from the pre-test to the post-test measurement (19 versus 7).
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Introduction
Poor sleep quality and daytime sleepiness are suspected causes of cognitive
impairment in obstructive sleep apnea (OSA) patients. Cognitive dysfunction ranges
from difficulties in attention and executive function to memory difficulties.
Continuous Positive Airway Pressure (CPAP) is the most consistently effective
treatment for moderate to severe OSA in adult, elderly, and dementia populations and
has been shown to improve cognitive impairment in these populations as well.
However, there are compliance issues that limit the effectiveness of this treatment.
Typically, the instruments used to study cognitive changes with CPAP use involve
extensive neuropsychological testing in research settings. Hence, it would be
beneficial for patients and physicians to measure this cognitive change through a time
sensitive screener such as the Montreal Cognitive Assessment (MoCA). In this project,
the objective was to determine whether the MoCA is a sensitive indicator of cognitive
improvement following introduction of CPAP in patients from a memory disorder
clinic who have been diagnosed with sleep apnea. Compliant and non-compliant
patients with a diagnosis of sleep apnea completed a MoCA before initiation of
treatment and again at a follow-up appointment. CPAP compliance was documented
through clinical interview with the patient and a family member during subsequent
medical visits. A review of the literature of sleep apnea and CPAP compliance was
examined to understand the cognitive impact of CPAP treatment on sleep apnea
patients and to further emphasize the need to improve compliance.
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Review of the Literature
Sleep Apnea
Sleep apnea (SA) is a common and serious sleep disorder that occurs when
breathing is briefly and repeatedly interrupted during sleep (Mayo Foundation for
Medical Education and Research, 2015). It affects about 18 million American adults
and an estimated 10 million Americans that remain undiagnosed (American
Association for Respiratory Care, 2016). The condition affects about 4 percent of
middle-aged men and 2 percent of middle-aged women (American Association for
Respiratory Care, 2016). Thus, the prevalence is higher among men than women.
Sleep apnea occurs in all ages including children and it is likely it may be passed on
across generations in families (American Association for Respiratory Care, 2016).
There are several factors that increase the risk of sleep apnea, such as being
overweight, having a large neck, small airways in their noses, throats, or mouths,
smoking, alcohol use, and belonging to certain ethnicities including African
Americans, Pacific Islanders, and Mexican-Americans, are at increased risk of
developing sleep apnea (American Association for Respiratory Care, 2016). Sleep
apnea has numerous adverse health consequences, such as high blood pressure, heart
attack, stroke, transient ischemic attacks, coronary heart disease, and the likelihood of
involvement in motor vehicle accidents is three times more likely (American
Association for Respiratory Care, 2016; National Institute of Neurological Disorders
and Stroke, 2015).
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Sleep apnea is characterized by brief interruptions of breathing during sleep
(NINDS, 2015). These interruptions involve at least 30 episodes of airflow cessations
per hour at the mouth and nose for more than 10 seconds (Yoshida, 2010). During
these periods of compromised breathing, arousal from sleep occurs to restore gas
exchange (Eckert et al., 2007). There are three main types of sleep apnea: obstructive
sleep apnea, the more common form, central sleep apnea, and a mixed or complex
sleep apnea syndrome that is a combination of the other two forms (Mayo Foundation
for Medical Education and Research, 2015). Common symptoms of both obstructive
sleep apnea and central sleep apnea include loud snoring (most important in
diagnosing obstructive sleep apnea), episodes of breathing interruptions, frequent and
sudden awakenings along with shortness of breath (more common in central sleep
apnea), dry mouth or sore throat, morning headache, insomnia, excessive daytime
sleepiness, attention and memory difficulties, and mood changes such as irritability
(Mayo Foundation for Medical Education and Research, 2015). Common
complications of sleep apnea are daytime fatigue, high blood pressure or heart
difficulties, type 2 diabetes, metabolic syndrome, complications with medications and
surgery, liver difficulties, and sleep deprivation (Mayo Foundation for Medical
Education and Research, 2015). Risk factors for obstructive sleep apnea include
obesity, which increases the risk four times compared to individuals with normal
weight, a neck circumference in men 17 inches and larger and 15 inches or more in
women, a narrowed airway, the male sex, older age, family history, use of alcohol,
sedatives or other substances that relax the muscles of the throat, smoking, which
increases the likelihood three times, and nasal congestion (Mayo Foundation for
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Medical Education and Research, 2015). In comparison, risk factors for central sleep
apnea include older age, heart disorders, narcotic pain medications, and history of a
stroke (Mayo Foundation for Medical Education and Research, 2015). On the other
hand, OSA has been identified as a potential risk factor for mild cognitive impairment
and other dementias. In a longitudinal study of 298 white women with a mean age of
82 years, sleep-disordered breathing was associated with an increased risk of cognitive
impairment, particularly mild cognitive impairment or dementia (Alzheimer’s disease;
Yaffe et al., 2011). Specifically, hypoxia measures were consistently associated with
mild cognitive impairment or dementia (Yaffe et al., 2011). After a mean of 4.7 years
of follow-up, 35.9% of women with sleep-disordered breathing developed mild
cognitive impairment and 15.8% developed dementia (Yaffe et al., 2011). Patients
with OSA are also at risk for subcortical ischemic vascular dementia (Roman,
Erkinjuntti, Wallin, Pantoni, & Chui, 2002). Subcortical ischemic vascular dementia is
due to small-artery disease and hypoperfusion, specifically complete infarction or
lacunar infarcts and microinfarcts, and incomplete infarctions of deep cerebral white
matter (Roman et al., 2002). The effects of OSA on cerebral microvascular and
neurovascular systems include mechanisms such as hypoperfusion, endothelial
dysfunction, and neuroinflammation (Kerner & Roose, 2016). Hypoperfusion leads to
the development or progression of cerebral small vessel disease (Kerner & Roose,
2016). In fact, intermittent hypoxia or a temporary absence of enough oxygen in the
blood plays a role in initiating and worsening these processes (Kerner & Roose, 2016).
Hypoxemia or low oxygen level in the blood also worsens the process resulting in
white matter lesions, white matter integrity abnormalities, and gray matter loss
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(Kerner & Roose, 2016). However, there is lack of research in the relationship
between vascular dementia and OSA, as well as in other dementias including frontal
temporal dementia, and Lewy Body Dementia.
Obstructive sleep apnea affects at least two to four percent of the adult
population in the United States (Eckert et al., 2007). Specifically, two to three times
greater in men than in women and in older adults ages 65 and older compared to
middle-aged individuals (Eckert et al., 2007). On the other hand, central sleep apnea is
seen in less than ten percent of patients presenting at sleep studies and in less than one
percent in the general population (Becker & Wallace, 2015). It affects males
predominantly and mostly affects middle-aged or elderly individuals with the
prevalence increasing among older individuals greater than 60 years (Becker &
Wallace, 2015). Therefore, the prevalence in patients with dementia is significantly
high with 70-80% having five or more apneas-hypopneas per hour of sleep and about
38-48% having 20 or more (Ancoli-Israel et al., 2008). The greater prevalence in
males is likely attributed to the presence of a lower apneic threshold of arterial oxygen
and carbon dioxide (PaCO2) in women compared to men (Becker & Wallace, 2015).
Therefore, a greater reduction in PaCO2 to initiate apnea is needed (Becker & Wallace,
2015). Moreover, different studies report the prevalence of complex sleep apnea
syndrome to be between 0.56 and 18% (Verbraecken, 2013). Differences in
prevalence data are due to CPAP titration, a supine sleep position, sleep duration,
opioid medication, ethnicity, and health conditions such as chronic health failure and
atrial fibrillation (Verbraecken, 2013).
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The most common type of sleep apnea, obstructive sleep apnea, is caused by
the relaxation of soft tissue in the back of the throat that blocks or narrows the passage
of air (NINDS, 2015). This soft tissue is made of muscles that support the soft palate,
uvula, tonsils, and the side walls of the throat and tongue (Mayo Foundation for
Medical Education and Research, 2015). Their collapse narrows or closes the airway,
limiting the level of oxygen breathed in and in turn lowering the level of oxygen in
your blood (Mayo Foundation for Medical Education and Research, 2015).
Consequently, the brain briefly awakens the person five to 30 times or more each hour
throughout the night to reopen the airway (Mayo Foundation for Medical Education
and Research, 2015). This brief awakening is snorting, choking, or a gasping sound
and disrupts the ability to reach a restful sleep (Mayo Foundation for Medical
Education and Research, 2015). In fact, many individuals with obstructive sleep apnea
are unaware of these interruptions and believe they received adequate sleep, while
experiencing fatigue and sleepiness during waking hours, especially when performing
tasks that require less attention (Mayo Foundation for Medical Education and
Research, 2015; Gagnon, et al., 2014). When waking up in the morning, individuals
also report headaches and dry throat (Gagnon, et al., 2014).
In comparison, central sleep apnea is a least common form and is caused by
irregular brain signals influencing breathing control and rhythm (Strohl, 2016). It is
defined by the lack of respiratory effort during cessations of airflow (Eckert, Jordan,
Merchia, & Malhotra, 2007). This contrasts with obstructive sleep apnea where
ongoing attempts of respiratory efforts are detected. Several manifestations of central
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sleep apnea include obesity hypoventilation syndrome, high altitude-induced periodic
breathing, idiopathic central sleep apnea, narcotic-induced central apnea, and CheyneStokes breathing (Eckert et al., 2007). Due to the increase of obesity over the years,
the prevalence of obesity hypoventilation syndrome is on the rise (Eckert et al., 2007).
However, idiopathic central sleep apnea is less common and may constitute less than
five percent of the population referred to a sleep clinic (Eckert et al., 2007). These
manifestations are classified into hypercapnic and nonhypercapnic groups based on
the wakefulness CO2 levels (Eckert et al., 2007). Overall, there is an overlap between
central sleep apnea and obstructive sleep apnea that suggest similar mechanisms. For
example, central respiratory events may lead to obstructive respiratory events in
patients with a particular pharyngeal anatomy (Eckert et al., 2007). Furthermore,
complex sleep apnea syndrome is initially diagnosed as an obstructive sleep apnea, yet
once treatment is initiated, there are frequent occurrences of central sleep apnea after
the elimination of obstructive events (Verbraecken, 2013). Therefore, although the
mechanism is not well known, complex sleep apnea is believed to be a combination of
an upper airway collapse and interrupted ventilator control (Verbraecken, 2013). A
hypothesis proposes an altered carbon dioxide excretion occurring when the upper
airway obstruction is opened through continuous positive airway pressure treatment
(CPAP; Verbraecken, 2013). This leads to a decrease in “carbon dioxide partial
pressure” and when this value falls below the “apneic threshold,” a central apnea will
develop (Verbraecken, 2013).
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Diagnosis
The most accurate way to diagnose sleep apnea is through a sleep study. The
most common sleep studies used are a nocturnal polysomnography (PSG) or a homebased portable monitor (NHLBI, NIH., 2012). In a nocturnal polysomnography, the
study records lung and brain activity, breathing patterns including movements through
the nose while you breathe, snoring, and chest movements, eye movements, arm and
leg movements, heart rate, and blood pressure while you sleep (NHLBI, NIH., 2012).
The test is performed at sleep centers or laboratories using sensors attached to the
scalp, face, chest, limbs, and a finger (NHLBI, NIH., 2012). Sleep stages are
monitored using 3 studies: electroencephalography (EEG), electrooculography (EOG),
and surface electromyography (EMG). Test results will confirm a diagnosis of sleep
apnea and will indicate the severity to determine the appropriate treatment.
Additionally, a PSG quantifies the number of respiratory events such as obstructive,
central, or complex, as well as the hypoxemia, or an abnormally low concentration of
oxygen in the blood, and arousals that result or occur independently from the
respiratory events (Armon, Nowack, & Johnson, 2016). In other cases, a home-based
sleep test using a portable monitor could also be recommended. This monitor records
the amount of oxygen in your blood, air movement through your nose while you
breathe, heart rate, and chest movements indicating your effort in breathing (NHLBI,
NIH., 2012). Test results would indicate a decrease in oxygen level during apneas and
subsequent awakenings (Mayo Foundation for Medical Education and Research,
2015). However, since these monitors do not detect all types of sleep apnea, a
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polysomnography could still be recommended (Mayo Foundation for Medical
Education and Research, 2015).
Impact on Cognition
Recent reviews of the neurocognitive effects of OSA have indicated deficits in
the cognitive domains of attention, episodic and verbal memory, and executive
functions (Stranks & Crowe, 2016). More specifically, there are reported deficits in
attention/vigilance, delayed long-term visual and verbal memory, and constructional
abilities (Stranks & Crowe, 2016). Reported cognitive complaints from patients with
untreated OSA in sleep centers are similar to these deficits, such as difficulties
concentrating on new tasks, attention, vigilance, performing monotonous tasks, and
difficulties with memory and learning new tasks (Vaessen, Overeem, & Sitskoorn,
2015). For example, frequent cognitive complaints include a decrease in alertness,
short-term memory problems, and a lack of concentration (Gagnon, et al., 2014).
However, findings on more specific memory complaints were inconsistent (Vaessen,
Overeem, & Sitskoorn, 2015). Regarding executive functioning, a study by Chen et
al. stated OSA patients reported complaints of emotional control and motivation rather
than abstract thinking and problem solving (Vaessen, Overeem, & Sitskoorn, 2015).
Despite these similarities, subjective cognitive complaints from OSA patients are not
necessarily related to objective cognitive functioning and many of these subjective
complaints are reported in the absence of objective cognitive impairments (Vaessen,
Overeem, & Sitskoorn, 2015). This is likely due to several reasons. First, cognitive
complaints could be secondary to other daytime OSA symptoms and are possibly
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unrelated to objective impairments in cognitive performance. Another reason may be
that subjective cognitive complaints are determined over a longer period, while
objective cognitive measures assess cognition at one point in time and under
controlled conditions (Vaessen, Overeem, & Sitskoorn, 2015). However, the
relationship between cognitive complaints and objective impairments warrant further
investigation since current studies primarily concentrate on the relation between
objective sleepiness and cognitive complaints (Vaessen, Overeem, & Sitskoorn, 2015).
In neuropsychological testing, the greatest deficits were found in psychomotor speed
and executive function, while tests measuring motor control, construction, attention,
and speed of processing abilities were less affected in patients with OSA (Stranks &
Crowe, 2016). However, more recent studies now support deficits in memory in OSA
patients (Stranks & Crowe, 2016).
The causal mechanism between cognitive impairment and OSA is unknown
and research continues to be in its infancy (Stranks & Crowe, 2016). A possible
explanation includes cognitive impairment resulting from long-term consequences of
regular intermittent hypoxia disrupting the blood-brain barrier and affecting the
brain’s microenvironment, as well as altering synaptic plasticity despite the bloodbrain barrier’s initial adaptivity (Stranks & Crowe, 2016). However, although
sleepiness and hypoxemia might cause the neuropsychological deficits seen in these
patients, many co-morbidities observed in these patients, such as obesity and
cardiovascular diseases, could also affect their cognitive functioning (Sforza & Roche,
2012). Moreover, a relationship between cognitive impairment and symptoms of OSA

11

has been identified in patients with dementia (Ancoli-Israel et al., 2008). For example,
a large study of patients in nursing homes demonstrated those with severe dementia
had significantly more severe OSA symptoms and those with severe OSA had
significantly more severe dementia (Ancoli-Israel et al., 2008). Although it is unlikely
OSA causes dementia, the hypoxia and sleep disruption from OSA might worsen
cognitive functioning (Ancoli-Israel et al., 2008).
Impact on Brain Structure and Function
Findings in a meta-analysis of fifteen studies identified consistent patterns of
structural atrophy and functional disturbances that occur due to OSA. These studies
demonstrated the involvement of the right basolateral amygdala/hippocampus
complex and the right central insular cortex that play an important role in the
subjective and objective cognitive and emotional complaints of OSA patients,
specifically affect, attention, and memory-related functions, and somatosensory
processing (Tahmasian et al., 2016). This area is part of a joint network that also
incorporates the anterior insular, posterior-medial frontal cortex, and thalamus
(Tahmasian et al., 2016). The hippocampus is known to be greatly affected by hypoxic
and hypercapnic episodes (Kloepfer et al., 2009). Structural damage to this area results
in cognitive deficits in memory, as well as attention and executive functioning due to
the role of the hippocampus in these functions, as well as its indirect functional
connections with the parietal and prefrontal cortex, which are also affected in OSA
(Ferini-Strambi et al., 2013).
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Impact on Mood
Affective disorders in patients with OSA occur frequently, yet vary widely (ElAd & Lavie, 2005). For example, depression is frequent in OSA patients, yet it does
not seem to be a universal finding (El-Ad & Lavie, 2005). This is likely due to many
other contributing factors influencing affective disorders, such as age, body mass, and
hypertension (El-Ad & Lavie, 2005). Other psychiatric disorders have been reported in
OSA patients such as anxiety, somatization, obsession-compulsion, and hostility (ElAd & Lavie, 2005). It appears that these affective disorders reported in OSA patients
may be influenced by the sleep disruption and intermittent hypoxemia caused by sleep
apnea (El-Ad & Lavie, 2005). Some models propose the involvement of the prefrontal
cortex due to the common impairment of executive functions in patients with sleep
apnea and state that it is particularly vulnerable to sleep disruption (El-Ad & Lavie,
2005). Specifically, sleep disruption and intermittent hypoxemia reduce the
effectiveness of sleep-related restorative processes and leads to the disruption of
homeostasis in certain regions of the brain (El-Ad & Lavie, 2005).
Treatment
Treatment for sleep apnea includes weight loss, positional therapy, treatment
of associated medical problems (i.e. improving therapy for heart failure may eliminate
central sleep apnea), oral appliance therapy, supplemental oxygen, continuous positive
airway pressure (CPAP), and surgical methods such as uvulopalatopharyngoplasty,
maxillomandibular advancement surgery, and tracheostomy (Yoshida, 2010). A 10%
reduction in weight leads to a 26% reduction in the respiratory disturbance index
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(RDI) and include numerous benefits such as improved pulmonary function and
arterial blood gas values, possible reduction of CPAP pressure required, and improved
sleep structure and snoring (Downey III, 2017). The purpose of oral appliance and
airway pressure devices is to adjust the position of the mandible or lower jaw and
tongue to enlarge the airway or reduce its collapsibility (Yoshida, 2010). Treatment
success is determined by measuring the apnea-hypopnea index (AHI) being less than
10 (Yoshida, 2010). An AHI more than 30 demonstrates significant
neuropsychological morbidity (Yoshida, 2010). Treatments are chosen from least
invasive and effective to most invasive and effective (Downey III, 2017). Nasal CPAP
therapy is offered first for patients suffering from mild to severe obstructive sleep
apnea (Downey III, 2017). For those who do not tolerate or refuse nasal CPAP
therapy, BiPAP therapy is the next recommendation followed by oral appliances
(Downey III, 2017). When noninvasive medical therapy fail, surgical procedures are
recommended. Moreover, pharmacological treatment is generally not recommended.
However, central nervous system stimulants such as modafinil and armodafinil are
used to treat fatigue and increase daytime wakefulness for patients who continue to
suffer from this symptom despite CPAP treatment (Downey III, 2017).
The most common and reliable therapy for sleep apnea is an airway pressure
device. CPAP is known as the most common and efficacious therapy for OSA (Mayo
Clinic, 2015). Based on Medicare guidelines, CPAP is recommended for all patients
with an AHI greater than 15 (Downey III, 2017). However, for patients with an AHI
of 5-14.9, CPAP is recommended only if they have one of the following symptoms:
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excessive daytime sleepiness, hypertension, and/or cardiovascular disease (Downey
III, 2017). CPAP contains an airflow generator that provides constant pressurized air
to prevent soft tissues in the airways from collapsing and becoming blocked (Wozniak
et al., 2014). This airflow is applied to the nose and directed through the upper airway
(Downey III, 2017). Physiological changes include an increase in lateral areas of the
upper airway and thinning of lateral pharyngeal walls that are thicker in patients with
OSA (Downey III, 2017). The CPAP machine consists of three main parts: a mask that
covers the nose or the nose and mouth, a tube that connects the mask to the motor, and
a motor that blows air into a tube (Wozniak et al., 2014). Current models are
lightweight, small, quiet, and are designed for daily use (Wozniak et al., 2014). During
or after a sleep study is conducted, proper titration is needed for CPAP machines
depending on the patient’s needs. Proper titration includes finding the minimum CPAP
level that eliminates obstructive apneas and/or hypopneas, oxyhemoglobin
desaturation, respiratory effort-related arousals, and snoring in all sleep stages and
positions (Downey III, 2017). However, current CPAP devices automatically change
pressures based on the presence and/or absence of OSA since it may vary over the
course of the night, sleep stages, and body positions not captured in the one-night
titration study (auto-positive airway pressure or auto-PAP; Downey III, 2017). CPAP
effectively resolves apneas and hypopneas, decreases arousals, and normalizes oxygen
intake (Downey III, 2017). Additionally, it has been shown to improve daytime
sleepiness, mood, quality of life, cognitive function, decrease health care costs, and
blood pressure in patients with mild to moderate sleep apnea (Downey III, 2017).
Most importantly, patients who use CPAP report an immediate improvement in
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alertness, concentration, and memory; however, maximum improvement in
neurocognitive symptoms is generally seen within 2 months of consistent CPAP use
(Downey III, 2017). Although CPAP has a better therapeutic effect than other
treatments, there are many problems that lead to noncompliant usage such as nasal
congestion, discomfort due to air-leak and pressure sensation, and mask intolerance
(Yoshida, 2010). Thus, patients with mild symptoms are more likely to discontinue
treatment.
Another similar airway pressure device is Bilevel Positive Airway Pressure
(BiPAP). In comparison to CPAP, instead of delivering a constant pressure during
both inspiration and expiration, BiPAP allows for an independent adjustment of
pressure during both events (Downey III, 2017). BiPAP is generally used in patients
who cannot tolerate high CPAP pressures, such as patients who suffer from difficult
exhalations or who have injuries caused by increased air or water pressure
(barotrauma; Downey III, 2017). However, generally this treatment is more expensive,
has no known advantages over CPAP therapy, and does not have better compliance
rates than CPAP (Downey III, 2017).
Since weight loss and positional therapies have not been effective in
completely resolving the issue, a variety of oral appliances have been used when
CPAP is not tolerated, or surgery is not recommended (Yoshida, 2010). Crossover
studies examining the efficacy of CPAP and oral appliances reported the effectiveness
of oral appliances in OSA patients, especially in mild to moderate cases due to fewer
side effects (Yoshida, 2010). In fact, the American Academy of Sleep Medicine has
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issued recommendations for the use of oral appliance therapy for simple snoring and
mild sleep apnea and for moderate to severe sleep apnea, if CPAP or BiPAP therapy is
not tolerated, and if patients do not respond to CPAP or BiPAP (Yoshida, 2010;
Downey III, 2017). Oral appliance therapy includes mandibular advancement
appliances and tongue retaining devices (Yoshida, 2010). Thus, a close collaboration
with a dental professional experienced in oral appliance therapy is necessary.
Mandibular advancement appliances are the most common and usually advance the
posture of the mandible at an elevated vertical and protrusive position (Yoshida,
2010). However, the protrusion distance of these devices can be adjusted after the
initial construction (Yoshida, 2010). Some appliances allow for flexible jaw
movements and are commonly used in orthodontics and to treat sleep apnea in
mentally impaired patients and patients with neuromuscular disabilities (Yoshida,
2010). In comparison, tongue retaining devices are used seldomly and usually when
there are dental complications (Yoshida, 2010). These devices work by holding the
tongue forward during sleep (Yoshida, 2010). The ideal treatment goal for oral
appliance therapy is an AHI of less than 5 without snoring (Downey III, 2017).
Adherence rates are not well defined and recorded due to a lack of objective measures
and a reliance on self-report. The main reasons for nonadherence with oral appliances
are temporomandibular joint problems, occlusal changes, excessive salivation,
discomfort, and ineffectiveness (Downey III, 2017).
Patients with severe sleep apnea usually require surgical methods to relieve
their obstruction. It is also indicated when conservative therapies are unsuccessful or
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not tolerated, as well as for patients who have a dental or jaw abnormality that could
be corrected through surgery (Yoshida, 2010). Additionally, a three-month trial of
other treatment options is suggested before considering surgery (Mayo Clinic, 2015).
The goal of surgery would be to enlarge the airway through the nose or throat; this
narrow airway may be causing the individual to snore or block the upper airway
passages causing sleep apnea (Mayo Clinic, 2015). For example, the most common
surgical procedure performed for patients with OSA is uvulopalatopharyngoplasty,
which removes tissue from the rear of the mouth and top of the throat that may be
contributing to the vibrating of structures leading to snoring, as well as reshaping the
soft tissues in the lateral pharyngeal walls (Mayo Clinic, 2015; Downey III, 2017).
Another procedure known as maxillomandibular advancement involves moving the
jaw forward to enlarge the space behind the tongue and soft palate; this procedure
eliminates the possibility of obstruction (Mayo Clinic, 2015). In more severe, lifethreatening sleep apnea cases, a procedure known as tracheostomy involves creating
an opening in the neck and inserting a metal or plastic tube to facilitate breathing
(Mayo Clinic, 2015). Although this is a nearly 100% effective surgery for OSA, it is a
disfiguring procedure and decreases the patient’s quality of life (Downey III, 2017).
Overall, the efficacy of these surgeries ranges from 30 to 50 percent and usually
involve possible complications such as pain and infection (Yoshida, 2010). Several
factors that increase the success of these surgical procedures are a lower AHI, lower
body mass index (BMI), the location of the collapse, the degree of mandibular
protrusion, and fewer comorbidities (Downey III, 2017). For example, surgeries
targeted to the collapse of the nasopharynx or oropharynx, as well as those addressing
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clear deficiencies in mandibular protrusion have a better outcome (Downey III, 2017).
Lastly, standard protocol for all patients undergoing surgery for treatment of OSA
involves a follow-up PSG (Downey III, 2017).
Furthermore, bariatric surgery has also been considered a therapy for OSA
with some nonrandomized, uncontrolled studies showing a decrease in AHI with
weight loss (Downey III, 2017). However, since studies have not examined pre- and
post-surgery AHI, included randomization of participants, and followed patients over
time, it is difficult to determine if a reduction of OSA symptoms is due to a placebo
effect (Downey III, 2017). Further research and ongoing clinical follow-ups are
needed to examine these effects.
CPAP Compliance
Consistent CPAP application has been shown to improve quality of sleep,
sleep architecture, neurobehavioral performance, reduces daytime sleepiness, lowers
blood pressure, reduces the risk for cardiovascular events, and even prevents
automobile accidents (Wozniak et al., 2014). CPAP has also been found to improve
overall quality of life and to some extent, cognitive dysfunction. A consensus among
the literature is the improvement of neuropsychological deficits such as attention,
executive functioning, and memory with CPAP usage (Aloia, Arnedt, Davis, Riggs,
Bryd, 2004). Crawford-Archour and colleagues revealed that CPAP treatment of at
least 6 hours per night allowed maintenance of memory, attention, and executive
functioning in the elderly population (Crawford-Archour et al., 2015). However, its
effectiveness is limited by poor compliance. Although evidence suggests about 68.5%
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of patients prescribed CPAP will accept their treatment, it is uncertain whether they
will remain compliant (Pertelle & Fary, 2007). Compliance refers to the length of time
a patient uses a CPAP machine on a nightly basis (Pertelle & Fary, 2007). It is
measured through subjective patient reports, an hour usage meter that records the
average number of hours used nightly, or a modem that reports overall CPAP usage
and pressure settings (Pertelle & Fary, 2007). Although there is no universal definition
of compliance for CPAP usage, a general clinical and empirical guideline for optimal
adherence across several studies is at least 4 hours (Pertelle & Fary, 2007;
Wohlgemuth, Chirinos, Domingo, & Wallace, 2015; Sawyer et al., 2011). These
studies also suggest a linear relationship between hours of CPAP usage and
improvements in functional abilities (Wohlgemuth et al., 2015).
Poor adherence is mainly caused by side effects involving discomfort with
CPAP usage, such as pressure sores from the nasal mask, dry, congested, and sore
noses and throats, silicon allergies, abrasion to the bridge of the nose, persistent air
leakage, chest discomfort, claustrophobia, and aerophagia or air swallowing (Sin,
Mayers, Man, & Pawluk, 2002; Pertelle & Fary, 2007). A review of CPAP adherence
reported that nasal anatomy such as smaller nasal cavities may impact CPAP
adherence by increasing nasal resistance (Sawyer et al., 2011).
There have been other covariates studied to understand difficulties with CPAP
adherence, such as age, gender, body mass index (BMI), residual AHI, daytime
sleepiness, OSA risk perception, and CPAP outcome expectation (Sin et al., 2002;
Wohlgemuth et al., 2015). In a study observing long-term compliance rates, they
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discovered several variables that were significantly correlated with increased CPAP
use. Among these were the female gender and increasing age (Sin et al., 2002). In
another study, residual AHI, CPAP pressure, length of time with CPAP, self-efficacy
for using CPAP, and insomnia severity distinguished clusters of patients who were
classified as adherers, non-adherers, and attempters (Wohlgemuth et al., 2015).
Findings from this study demonstrated that patients who attempted CPAP treatment
and had a lower AHI and lower CPAP pressure would likely not appreciate the daily
benefits from daily CPAP use and thus would not use the treatment for longer periods
of time (Wohlgemuth et al., 2015). Other covariates reported in the literature as an
important influence in CPAP adherence are self-efficacy and insomnia. Self-efficacy
or the confidence in their ability to use CPAP when faced with difficulties may be
more strongly related to frequency of CPAP use rather than duration of use (Lewis et
al., 2004; Wohlgemuth et al., 2015). However, insomnia appears to be a more
common barrier to adequate CPAP use than level of self-efficacy and is also a
common comorbidity with untreated OSA (Wohlgemuth et al., 2015). Patients with
severe insomnia either do not try CPAP due to the expected sleep difficulty with
treatment or may begin sleeping with CPAP yet remove it later in the night due to
difficulty staying or falling asleep (Wohlgemuth et al., 2015). Overall, the group of
non-adherers had lower levels of self-efficacy for CPAP use and more severe
insomnia (Wohlgemuth et al., 2015). Another study identified outcome expectancies
or the patient’s expectations for specific responses to CPAP treatment, as well as AHI
and self-efficacy are significant contributors to CPAP adherence (Baron et al., 2010).
Additionally, they reported active coping styles with challenging situations, including
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aggressive efforts to alter situations and planned problem solving were associated with
higher rates of CPAP use (Baron et al., 2010).
Another influence on CPAP adherence is a patient’s race. Although research
on different race and ethnic groups continues to be in its infancy, most studies have
reported lower CPAP adherence in African Americans versus Caucasian patients (Platt
et al., 2009). This may be due to socioeconomic status (Platt et al., 2009). Therefore,
the need for individualized considerations with culturally diverse patients are needed
when examining adherence outcomes in CPAP treatment (Platt et al., 2009).
Additionally, a study found that patients who experienced some significant life event 6
months prior to CPAP treatment had significantly lower CPAP use than those who did
not suffer from a recent life event (Lewis et al., 2004). This study and others also
reported findings that patients who lived alone used CPAP significantly less than those
who had a bed partner and had spousal involvement with CPAP experience and use
(Lewis et al., 2004; Baron et al., 2010).
The health and functional importance of CPAP adherence has led to an
extensive amount of research on interventions that would effectively improve CPAP
use. In a meta-analysis study that examined three groups of interventions including
educational, supportive, and behavioral, they found that all types of interventions had
a positive impact on increasing average CPAP machine usage and number of
participants compliant with treatment over a short amount of time (Wozniak et al.,
2014). However, behavioral interventions resulted in the largest improvement in
average hours of CPAP use (Wozniak et al., 2014). The educational interventions used
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included written materials, verbal sessions, and/or audio-visually delivered
information about OSA and CPAP treatment (Wozniak et al., 2014). Supportive
interventions included regular meetings, telephone follow-ups, and/or interactive
applications to encourage continued use of CPAP and motivate participants to report
problems associated with its usage (Wozniak et al., 2014). The key feature in this type
of intervention was the frequent encouragement of feedback on their experience of
CPAP treatment (Wozniak et al., 2014). Behavioral interventions involved methods to
modify and promote adherence behaviors, such as motivational interviewing
techniques and cognitive behavioral therapy (Wozniak et al., 2014; Aloia et al., 2001).
CPAP Compliance and Mood
Although a greater percentage of patients achieve better functioning with
longer CPAP use, studies have shown a significant number of patients will not return
to normal functioning or experience daytime symptom improvement despite adequate
use of CPAP (Antic et al., 2011). Recent studies have examined depression and other
mood disturbances and their relationship to CPAP adherence as an explanation for
these cases. In one study, a patient’s perceptions of sleep apnea symptoms,
improvement of symptoms after CPAP treatment, and a patient’s perception of their
experience with side effects from CPAP usage were different between patients who
were diagnosed with and without depression prior to initiating CPAP treatment
(Wells, Freedland, Carney, Duntley, Stepanski, 2007). In this study, there was a
strong association between self-reports of depressive symptoms and OSA symptoms,
which likely reflects the oversensitivity to symptoms and/or over-reporting of
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symptoms in self-report measures with depressed patients (Wells et al., 2007).
Symptoms of fatigue, low energy, insomnia, and altered sleep patterns are common
symptoms in both depression and OSA (Wells et al., 2007). Thus, patients with
depressive symptoms who are complaint with CPAP treatment are more likely to
report continued fatigue and/or sleepiness (Wells et al., 2007). Similarly, individuals
who experienced an improvement with depressive symptoms also reported an
improvement in OSA symptoms (Wells et al., 2007). It was also suggested in this
study that depressive symptoms may respond differently during CPAP treatment,
depending on whether they developed prior to OSA or were secondary to OSA (Wells
et al., 2007). Overall, this study emphasized the importance of inquiring about
depressive symptoms if an individual does not report an improvement with fatigue or
sleepiness after using CPAP appropriately (Wells et al., 2007). Additionally, another
study examined patients with personality traits of negative affectivity and social
inhibition that perceived a higher severity and frequency of side effects associated
with CPAP usage (Brostom et al., 2007). However, there are also studies that have
shown a depression diagnosis at the initiation of CPAP treatment has no influence on
CPAP usage (Lewis, Seale, Bartle, Watkins, & Ebden, 2004; Stepnowsky, Bardwell,
Moore, Ancoli-Israel, Dimsdale, 2002). Nonetheless, it is important to consider other
mood disturbances or other medical comorbidities contributing to any neurobehavioral
disturbance experienced after CPAP treatment (Antic et al., 2011).
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CPAP’s Impact on Cognition, Brain Structure and Function
One of the most concerning adverse consequences of OSA is impairment in
cognitive functioning. This impairment has implications for social functioning,
everyday activity, and occupational performance (Kielb et al., 2012). In their review
of the cognitive effects of CPAP compliance, Aloia et al. (2004) described
improvements in attention and vigilance in most of the studies reviewed, while global
functioning, executive functioning, and memory improved in only some studies. This
variability may likely be due to many reasons, such as study design (within-subject
and between-subject designs), neuropsychological tests selected that may vary in
sensitivity to the effects of treatment, and even practice effects in neuropsychological
testing (Ferini-Strambi, Mareli, Galbiati, & Castronovo, 2013). A within-subjects
design study reported an improvement in verbal memory in patients using CPAP for
an average of six hours a night (Zimmerman, Arnedt, Stanchina, Millman, & Aloia,
2006). Similarly, Aloia and colleagues reported improvements in attention and
executive function after 3 months and 6 months of follow-up (Aloia et al., 2003). In
comparison, a between-subjects design study reported improvements in attention,
spatial ability, and motor speed in patients compliant with CPAP treatment after 15
days of follow-up and after four months (Ferini-Strambi et al., 2003). Other studies
considered adherence to CPAP a significant factor when evaluating cognitive effects
of CPAP treatment. Zimmerman and colleagues observed that memory performance
may be reversible with optimal levels of CPAP treatment and OSA patients with
memory deficits initially may need at least six hours of CPAP use per night to
experience benefits in memory functions (Zimmerman et al., 2006).
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In elderly patients 65 years and older with OSA, long-term CPAP treatment
was observed to have a protective effect on cognitive performance (Crawford-Archour
et al., 2015). This study allowed the maintenance of several cognitive functions
including memory (delayed free recall), attention, and executive functioning (WAIS
III Similarities test) and reported adequate self-reported CPAP compliance of at least 6
hours per night (Crawford-Archour et al., 2015). In a randomized, multicenter clinical
study of 224 elderly patients 70 years and older with severe sleep apnea, one of the
main findings included an overall improvement in all neurocognitive tests in the
treatment group, yet more significant changes were observed in tests related to
working memory and executive functions (Martinez-Garcia et al., 2015). The
extensive neuropsychological battery included executive functioning, visual attention,
speed of processing and mental flexibility (Trails Making Test A and B) and working
memory (digit symbol and digit span tests; Martinez-Garcia et al., 2015). Furthermore,
due to the high prevalence of OSA in patients with dementia, studies have also
investigated cognitive effects of CPAP treatment in this population. In a randomized
placebo-controlled CPAP trail in mild-moderate AD patients with OSA, composite
neuropsychological scores from treatment groups suggested modest statistically
significant improvements in cognitive functioning with three weeks of CPAP
treatment (Ancoli-Israel et al., 2008). Their neuropsychological battery measured
cognitive abilities of learning and memory, frontal/executive skills, attention and
vigilance, and mental processing speed (Ancoli-Israel et al., 2008). Exploratory posthoc examination of change scores for individual neuropsychological tests
demonstrated improvements in episodic verbal learning and memory, as well as
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improvements in executive functioning tasks such as cognitive flexibility and mental
processing speed (Ancoli-Israel et al., 2008). The results of this study support the
implication that OSA might be a reversible cause of cognitive impairment in patients
with dementia and CPAP treatment when used in the early stages of the dementia may
even slow the progression of the disease (Bliwise, 1996).
Canessa and colleagues reported cognitive and structural improvements after 3
months of CPAP treatment (Canessa et al., 2011). Since memory impairments have
been observed in patients with OSA, Canessa and colleagues observed hippocampal
structures, which are sensitive to hypoxic damage associated with OSA (Gozal, Row,
Schurr, 2001). Hippocampal damage may also be associated with the attentional and
executive impairment seen in patients with OSA due to the extensive connections
between the prefrontal cortex and thalamus (Newbery & Iversen, 2003). Canessa and
colleagues observed an increase in volume in the hippocampus (left subiculum and
bilateral entorhinal cortex), the medial orbitofrontal cortex, and the rostral portion of
the right superior frontal gyrus (Canessa et al., 2011). The increase in volume of the
entorhinal cortex was correlated with improvements in verbal and visuospatial shortterm memory, attention, and executive functioning (Canessa et al., 2011). This study
reported the mechanism of brain change after CPAP treatment is likely vasogenic,
which is similar to neuropsychological changes seen with mild cerebrovascular
disease or small vessel disease (Canessa et al., 2011).
During the initial diagnostic phase of OSA, it is likely that an individual first
visits their primary care physician. If the individual is prescribed a sleep study and is
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recommended for CPAP treatment, it is possible they would be apprehensive to adhere
to daily CPAP treatment due to reported side effects, such as discomfort with CPAP
usage, pressure sores from the nasal mask, dry, congested, and sore noses and throats,
silicon allergies, abrasion to the bridge of the nose, persistent air leakage, chest
discomfort, claustrophobia, aerophagia or air swallowing, and nasal resistance (Sin et
al., 2002; Pertelle & Fary, 2007, Sawyer et al, 2011). Potential cognitive
improvements from CPAP treatment are evident in extensive neuropsychological
testing. However, this testing is primarily used in research settings and is difficult to
perform in the elderly and dementia populations who have a high prevalence of OSA.
Therefore, it would benefit physicians to be able to measure this cognitive change in
an efficient, yet feasible manner. This evidence of cognitive improvement would be
provided to patients and may likely improve compliance. In this present study, the
objective was to measure this cognitive change through a time sensitive screener, the
MoCA, in an elderly dementia population with OSA and assess its sensitivity in
detecting cognitive change following CPAP treatment.
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Purpose and Hypotheses
The purpose of this study was to investigate whether the MoCA test is
sensitive to the level of cognitive change that occurs in patients who suffer from sleep
apnea and undergo CPAP treatment. Being a quick cognitive screener, the MoCA test
would be a time sensitive and efficient tool in medical health care settings, such as in
memory disorder clinics, when determining the effect of CPAP treatment. Improved
cognition in dementia patients could increase independence, thus relieving caregiver
burden, and disease-related costs and resources (Ancoli-Israel, 2008). The following
was proposed in this study: 1) The MoCA test will be a sensitive indicator of cognitive
change following introduction of CPAP in patients with sleep apnea, and 2) Patients
who used CPAP will demonstrate significant improvement in MoCA performance
compared to non-compliant patients.
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Method
Participants
Archival participant data from the Health First Aging Institute and the East
Central Florida Memory Disorder Clinic (ECFMDC) was utilized for this study. The
participants were patients from ECFMDC with a wide variety of dementia diagnoses
including: no cognitive impairment, Alzheimer’s disease, mild cognitive impairment,
cognitive disorder NOS, and other dementia, who were also diagnosed with sleep
apnea and recommended for CPAP treatment. Twenty-six CPAP compliant (61.5%
male; 96.2% Caucasian/Non-Hispanic), ages 66-87 years (M=76.27(4.90)) and
Twenty CPAP non-compliant patients (85% male, 100% Caucasian/Non-Hispanic)
ages 66-90 (M=77.45 (6.88)) were chosen from a research database. Inclusion criteria
involved memory disorder clinic patients who completed a sleep study, were
diagnosed with sleep apnea, and were recommended for CPAP treatment.
Additionally, pre- and post-CPAP treatment MoCA administrations of no more than 9
months apart were also required for inclusion in the study. All Health First Aging
Institute patients consent to the use of their test data and relevant medical records for
the purposes of research during their initial appointment. Informed consent is also
obtained prior to each patient’s neuropsychological testing. Patients are presented with
a form explaining the use of de-identified results for research purposes. Lastly, the
research has been approved by the Florida Institute of Technology’s Institutional
Review Board.
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Measures and Materials
The MoCA test was used as a pre- and post-treatment measure of cognitive
change for CPAP compliant and non-compliant groups. The MoCA is a brief, 10minute, pen-and-paper screening instrument that is useful in detecting mild cognitive
impairment and dementia. Scores may range form 0 – 30 and are equal to or greater
than 26 when considered to be within the normal range of functioning. The MoCA test
assesses several cognitive domains including attention, concentration, executive
functions, memory, language, visuospatial skills, abstraction, calculation and
orientation (Julayanont et al., 2012).
Patients suspected of having sleep apnea were referred to sleep clinics to
obtain a sleep study and were then prescribed CPAP treatment, if diagnosed with sleep
apnea. CPAP contains an airflow generator that provides constant pressurized air to
prevent airways from collapsing and becoming blocked. It consists of three main parts:
a mask that covers the nose or the nose and mouth; a tube that connects the mask to
the motor; and a motor that blows air into a tube. Current models are lightweight,
small, quiet, and are designed for daily use (Wozniak et al., 2014).
Procedure
The MoCA test was given prior to CPAP treatment recommendation and at
follow-up 4-9 months later for both compliant and non-compliant groups. CPAP
compliance was determined through monthly compliance reports sent directly from
the CPAP machine smart card to the pulmonologist and/or clinical interview with
patient and family members during subsequent medical visits at the East Central
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Florida Memory Disorder Clinic. Pre-and post-CPAP treatment MoCA test scores
were compared and assessed for change.
The study consisted of an archival investigation. It consisted of patients from
the East Central Florida Memory Disorder Clinic who completed a sleep study, were
diagnosed with sleep apnea, and received a recommendation for CPAP treatment.
Additional inclusion criteria included participants who received a MoCA test in a
medical visit prior to CPAP initiation and after.
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Statistical Methods
All data were analyzed using SPSS, versions 23 and 24. Pre- and posttreatment MoCA score change as a function of CPAP compliance was analyzed using
a mixed model analysis of variance. Specifically, MoCA scores before and after CPAP
treatment for CPAP compliant and noncompliant CPAP groups were observed. As
such, a control group was not necessary as we were controlling variables by
comparing them to themselves. CPAP compliance and non-compliance were the
between-subject group, while the pre- and post-CPAP treatment scores were the
within-subject groups. The goal was to determine if a statistically significant
difference exists in MoCA scores for those patients selected for the pre-and posttreatments. Overall, these analyses provide an answer as to whether the use of MoCA
is sensitive enough to detect change in cognitive functioning following CPAP
treatment in sleep apnea patients. The interaction between diagnoses and compliance
was also observed using a crosstabs analysis.
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Results
Prior to tests of hypotheses, the equivalence of group make-up by sex and age
was examined. A Mann-Whitney U-test indicated no significant difference between
sex across compliance groups, U= 199.00, p= .083, r= .26. Groups also did not differ
on age as determined with an independent samples t-test, t (44) = -0.680, p=0.500.
Figure 1 displays the frequency of patient diagnoses in both compliance groups. Most
patients in the compliant group (pre- MoCA M= 20.38, post- MoCA M= 22.27) had an
AD diagnosis, while most of the non-compliant group (MoCA pre- M= 19.90, MoCA
post- M= 20.50) had a dementia or cognitive disorder NOS diagnosis. Cross tabulated
frequencies demonstrated no significant relationship between compliance groups and
diagnosis, X2 (3, N = 46) = 2.68, p = 0.44. The compliant group had 7 individuals
within normal limits (WNL), 6 mild cognitive impairment (MCI), 9 Alzheimer’s
disease (AD), and 4 individuals with other dementia or cognitive disorder NOS. In
comparison, the non-compliant group had 3 individuals WNL, 4 MCI, 6 AD, and 7
individuals with other dementia or cognitive disorder NOS diagnosis. Figure 2
displays the frequency of patient mood disorder diagnoses in both compliance groups.
Although most patients in both compliance groups did not have a depression and/or
anxiety disorder diagnosis, for those diagnosed with a mood disorder, most had both a
depression and anxiety diagnosis. Cross tabulated frequencies demonstrated no
significant relationship between compliance groups and mood disorder diagnosis, X2
(3, N = 46) = 0.26, p = 0.97. The compliant group had 3 individuals with a depression
diagnosis, 1 with anxiety, 5 with depression and anxiety, and 17 with no mood
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disorder diagnosis. Similarly, the non-compliant group had 3 individuals with a
depression diagnosis, 1 with anxiety, 3 with depression and anxiety, and 13 with no
mood disorder diagnosis.
Figure 1
Frequency of patient diagnosis in CPAP compliance groups
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Figure 2
Frequency of patient mood disorder diagnosis in CPAP compliance groups

On another analysis, a Pearson product-moment correlation coefficient was
computed to assess the relationship between the interval of time from pre- and posttreatment MoCA scores (days) and MoCA scores (change scores) across both CPAP
compliant and non-compliant groups. Results demonstrated no association between
the interval of time and MoCA scores in any of the CPAP compliance groups, p =
0.578 (CPAP compliant group), p = 0.681 (CPAP non-compliant group).
Table 1 depicts pre- and post-treatment MoCA score changes as a function of
CPAP compliance. Post-treatment MoCA scores for the CPAP compliant group were
significantly higher than pre-treatment. Nineteen of the 26 compliant patients
evidenced increases in MoCA, three remained the same, and four declined. The non-
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compliant group showed no change over time, with seven scores decreasing, 11
increasing, and two remaining the same. Most importantly, 19 of the 26 compliant
patients demonstrated improvements in MoCA scores, while only 11 of the 20 noncompliant patients improved.
Table 1
Changes in MoCA scores as a function of CPAP compliance
Pre-Treatment MoCA
Scores
M
SD
Compliance 20.38
4.02
Non19.90
4.13
Compliance

Post-Treatment
MoCA Scores
M
SD
22.27
3.94
20.50
4.15

T-test

Pvalue

-4.992
-.798

0.00
0.44

Table 2
MoCA scores for CPAP compliance and non-compliance groups before and after
CPAP treatment

Pre-treatment
Score
Post-treatment
Score

CPAP
Compliance
n
M
SD
26
20.38 4.02

CPAP Non-Compliance
n
20

M
19.90

SD
4.13

26

20

20.50

4.15

22.27 3.94

A mixed model analysis of variance was conducted to assess the interaction of
CPAP compliance (CPAP compliant and non-compliant groups) on MoCA scores
across the two-time periods, pre-CPAP treatment and post-CPAP treatment (MoCA
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change scores). There was no significant interaction between CPAP compliant groups
and MoCA change scores, Wilks’ Lambda= .94, F (1, 44) = 2.67, p=.109, partial eta
squared= .057. There was a substantial main effect for MoCA change scores, Wilks’
Lambda= .82, F (1, 44) = 9.99, p = .003, partial eta squared = .185. Wilks’ Lambda
test was selected as the multivariate test due to its greater statistical power. The main
effect comparing change in the compliance groups was not significant, F (1, 44) =
.981, p = .327, partial eta squared = .022.
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Discussion
CPAP treatment has been shown previously to improve performance in
neuropsychological measures that might be impacted by sleep apnea (Shranks &
Crowe, 2016). However, the extensive neuropsychological testing needed to examine
this cognitive change is a difficult task with the elderly and patients with dementia.
Since there is a high prevalence of sleep apnea in the elderly and dementia population
(Ancoli-Israel et al., 2008), it would be advantageous for patients and physicians to
utilize a quick and short screener to assess the usefulness of CPAP treatment. This
evaluation would be a more time and cost-efficient procedure to evaluate the
effectiveness of CPAP treatment in the elderly.
The results of the current study suggest the MoCA test is sensitive to the level
of change that occurs in patients who differ considerably in cognitive ability. First, it
is important to note that the estimation of cognitive ability based on the total score of
the MoCA is not necessarily linear (Koski, Xie, & Finch, 2009). Thus, a decline is not
equally significant at all levels of ability (Koski, Xie, & Finch, 2009). For example, a
score of 20/30 does not signify an individual has twice as much cognitive ability as an
individual with a score of 10/30 (Koski, Xie, & Finch, 2009). A study by Koski and
colleagues, generated a Rasch analysis that allowed a linear estimate of cognitive
ability on an interval-like scale for any given MoCA score measured at 2 points in
time (Koski, Xie, & Finch, 2009). The study presented a table used to determine the
statistical significance of a change in the total MoCA score depending on the baseline
score (Koski, Xie, & Finch, 2009). In another study, Krishnan et al. (2016) explored
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the utility of the MoCA in the detection of cognitive change in a 3.5-year period in a
sample of individuals who were cognitively intact compared to a sample diagnosed
with mild cognitive impairment (MCI). After adjusting for age and education, their
results demonstrated a change in MoCA scores in the MCI group of -1.70, while the
cognitively intact group was -.75 (Krishnan et al., 2016). Thus, individuals who were
cognitively intact demonstrated stable MoCA scores over a 3.5-year period, while
individuals with MCI demonstrated a significant decline in scores (Krishnan et al.,
2016). Overall, a reliable change of 1.73 points in this period represented a clinically
meaningful difference (Krishnan et al., 2016). However, the clinical significance of a
change in MoCA scores in other levels of ability warrants further investigation.
In this current study, patients with SA who used CPAP demonstrated improved
MoCA performance. Nineteen of the 26 compliant patients demonstrated
improvements in MoCA scores, while only 11 of the 20 non-compliant patients
improved. These findings suggest the MoCA test is sensitive to the level of cognitive
change that occurs in patients with sleep apnea. Therefore, it is possible to use the
MoCA test when determining CPAP effect. This assessment would be beneficial in
general healthcare settings, such as a primary care clinic, as well as specialty clinics,
such as a memory disorder clinic, to assess cognitive change after CPAP usage in a
time and cost-efficient manner. Most importantly, detecting this cognitive change
would increase CPAP compliance and thereby improve cognition in dementia patients.
Cognitive improvement from CPAP treatment has the potential to improve quality of
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life, relieve caregiver stress, and minimize disease-related costs and resources in the
elderly and dementia populations.
When pre-CPAP treatment MoCA scores were compared to post-CPAP
treatment MoCA scores in each compliance group, there was no significant difference
in MoCA change scores between CPAP compliant and non-compliant patients. The
different outcomes of CPAP effects shown by the repeated measures t-tests
(improvement for compliant group only) and mixed-model ANOVA (no difference in
the change scores between the two compliance groups) could be explained by the t-test
reducing within subject variability sufficiently to show a significant outcome despite
the relatively low group size of 26. In the mixed-model ANOVA, the change scores of
the two groups were compared directly, and relatively large variability in the noncompliant group made finding a significant outcome unlikely.
When examining the distribution of CPAP compliant and non-compliant
patients with different diagnoses, diagnosis did not impact the findings of this study.
Therefore, compliance and diagnosis are independent from one another and
demonstrated no relationship. However, a larger, more representative sample is needed
to further explore the relationship or impact of different levels of cognitive ability or
diagnoses on CPAP compliance.
Limitations
There are several limitations to the present study. First, a small sample size was
used, which likely hindered results. This was due to the limited number of patients who
met criteria for the study including a sleep apnea diagnosis, records of a sleep study that
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was performed during the time they were an active patient in the memory clinic, a
neuropsychological evaluation during the time the patient began their CPAP treatment,
and having a MoCA administration prior to CPAP treatment and after CPAP treatment
of no more than 9 months apart. The sample size was also lacking in diversity as most
patients were white, Caucasians. Nonetheless, the sample is representative of the
geographic location where the study took place. It is also important to note most of the
patients in the sample had a dementia diagnosis. The neurodegenerative nature of their
disease continues to affect their cognitive performance despite the benefit CPAP
treatment.
Another limitation was the Electronic Medical Record (EMR) System, which
affected data collection and analysis. There were numerous patients who did not have
records of their sleep study, no neuropsychological evaluation, were not administered
the MoCA at the 6-month follow-up or given the MoCA more than 9 months after the
pre-CPAP treatment MoCA score, and providers failed to follow-up on CPAP
compliance on some occasions. Additionally, in most cases, there was a lack of records
for CPAP compliance reports generated by the CPAP machine and sent electronically
to the pulmonologist. In these cases, CPAP compliance was confirmed by self-report in
the memory clinic records. Additionally, there was limited resources to recruit patients
due to research restrictions of the Brevard County Health First medical system.
Authorization for research was only provided to the memory clinic rather than other
primary care or specialty providers.
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Future Directions
Future research should focus on improving statistical power by increasing
sample size, as well as in utilizing a large, more representative sample of various
racial and ethnic backgrounds. Another improvement to this study would include
assessing its reliability. Since the time interval between the initiation of CPAP
treatment and after treatment was highly variable, a prospective study would be
helpful to serve as a comparison when the time interval is held constant.
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